SequelSEC

Surrozen, Inc./DE SRZN

Biological Products, (No Diagnostic Substances) · CIK 0001824893 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$11.51M
Fiscal year ended 2026-06-30
Operating income
-$44.35M
Fiscal year ended 2026-06-30
Free cash flow
-$34.98M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$59.70MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.20Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue17.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-67.4%16th
Net margin-6960.8%20th
Current ratio9.22x79th
SBC / revenue110.3%68th
FCF margin-873.5%35th
Operating margin-1210.6%36th
R&D / revenue844.5%62th
CapEx / revenue3.7%50th

Surrozen, Inc./DE (SRZN) reported revenue of $11.51M and net income of -$332.13M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Surrozen, Inc./DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Surrozen, Inc./DE income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$11.51M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$44.35M
Net income-$332.13M
Research & development$34.58M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$21.28M
Selling & marketingUnavailable

Balance

Surrozen, Inc./DE balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$102.04M
Total assets$115.61M
Current assets$109.40M
Total liabilities$334.27M
Current liabilities$9.01M
Total equity incl. NCI-$218.66M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$5.00M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.07M

Cash flow

Surrozen, Inc./DE cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$34.76M
Capital expenditures$222.00K
Investing cash flow-$222.00K
Financing cash flow$46.58M
Net change in cash$11.60M
Stock-based compensation$7.00M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$222.00K

Derived

Surrozen, Inc./DE derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$34.98M
Gross marginUnavailable
Operating margin-385.3%
FCF margin-303.9%
SBC / revenue60.9%
Current ratio12.14x
Revenue YoY growth-8.8%
Net margin-2885.3%
R&D / revenue300.4%
CapEx / revenue1.9%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SRZN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.